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ABSTRACT
Objectives: A recent systematic review confirmed the
usefulness of fecal calprotectin (FC) in distinguishing
organic (inflammatory bowel disease (IBD)) from
non-organic gastrointestinal disease (irritable bowel
syndrome (IBS)). FC levels <50 μg/g have a negative
predictive value >92% to exclude organic
gastrointestinal (GI) disease. Levels >250 μg/g correlate
with endoscopic IBD disease activity; sensitivity 90%.
We aimed to determine clinical outcomes in
intermediate raised FC results (50–250 μg/g).
Setting: Primary care general practices in Coventry and
Warwickshire, and 3 secondary care hospitals.
Participants: 443 FC results in adults (>16 years old)
were reviewed from July 2012 to October 2013. Clinical
data was collected from hospital databases and general
practitioners. Long-term clinical data was available in 41
patients (out of 48).
Primary and secondary outcome measures: The
number of new diagnoses of IBD, IBS and other
diagnoses for the intermediate group. The number
referred and discharged from secondary care.
Results: A new IBD diagnosis was made in 19% (n=8)
of intermediate results (1% of normal and 38% of
raised results). 5% (n=2) of intermediate results had
known IBD in remission. A new IBS diagnosis was
made in 27% (n=11) of intermediate results, while 34%
(n=14) remained undiagnosed, although 8 of these were
not referred to secondary care.
Conclusions: FC testing remains useful in aiding
diagnosis of organic GI conditions. However, unlike
negative and strongly positive FC results, intermediate
FC results lead to a mixture of diagnoses. The OR of a
new diagnosis of IBD for an intermediate result
compared to normal FC result was 26.6, while an
intermediate FC result gave an OR of 0.54 for a new IBS
diagnosis compared to normal FC. For intermediate FC
results, 1 in 3 patients remained in secondary care after
12 months with an OR of 3.6 compared to a normal FC
result.
INTRODUCTION
Calprotectin is a calcium binding protein of
the S100 family, found mainly in neutrophils
but also in other white blood cells.1
Inﬂammation results in neutrophil activation
and a subsequent release of calprotectin
protein.2 3 The use of fecal calprotectin (FC)
has particular interest as a non-invasive bio-
marker in the initial screening and monitor-
ing of patients with suspected or known
inﬂammatory bowel disease (IBD).4 It is of
particular use in the distinction between
inﬂammatory gastrointestinal (GI) condi-
tions such as IBD, from non-organic condi-
tions such as irritable bowel syndrome
(IBS).5 FC testing also has a growing role in
the monitoring of IBD activity in response to
treatment, although long-term data on the
clinical advantages of this approach are not
yet available.6
Current National Institute of Health and
Care Excellence (NICE) and manufacturer
guidelines for the cut-off levels of FC in
assays are that levels of <50 μg/g of feces
suggest that there is no active inﬂammation
present within the GI mucosa.5 7 NICE
reported that for most of the studies they
reviewed, sensitivity and speciﬁcity were over
80%, where a cut-off of 50 μg/g was used,
and most positive and negative predictive
values were 70–90%.7 One recent study
found that a cut-off of 50 μg/g gives a sensi-
tivity and speciﬁcity of 88% and 78%,
Strengths and limitations of this study
▪ Twelve-month clinical follow-up data of inter-
mediate fecal calprotectin results.
▪ A ‘real-world’ view of the usefulness of FC
testing in primary and secondary care—it is not
being used in an entirely appropriate manner.
▪ A ‘real-world’ view of clinical outcomes—we
don’t always find the answer.
▪ Heterogeneous data sources means data is not
as complete as it could be, for example, medica-
tion information incomplete.
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respectively, with a negative predictive value of >92% to
exclude organic GI disease.8 A cut-off value of 100 μg/g
has previously been suggested, and while this increases
sensitivity to 97%, speciﬁcity falls to 76%, with a negative
predictive value of 97%, and a positive predictive value
of 75%.8 A cohort study involving consecutively referred
new patients with chronic diarrhoea proposed that a
cut-off of 8 μg/g provides near 99% sensitivity in detect-
ing organic disease but at the cost of poor speciﬁcity.9 In
this study, no patients were diagnosed with IBD with FC
levels of 50 μg/g or less, although this was a small study,
hence, only a few patients overall with IBD. Another
study found that no patients with an FC result of
<100 μg/g had IBD.10 A systematic review of the use of
FC, which informed the NICE diagnostic assessment
group, found that most of the available evidence for FC
use in IBD is based on a cut-off value of 50 μg/g which
reduces the number of false negatives while maintaining
cost-effectiveness.5 7
An FC value of >250 μg/g has been demonstrated
to correspond with endoscopically and histologically
active IBD. This cut-off level provides a sensitivity of 90%
and speciﬁcity of 76% for excluding IBD, and also deter-
mining if known disease was quiescent.8 A recent
meta-analysis into the utility of FC testing for monitoring
disease activity showed that for known IBD, a cut-off
level of 50 μg/g gave a pooled sensitivity and speciﬁcity
of 92% and 60% for determining if disease was quies-
cent, a cut-off of 100 μg/g gave 84% and 66%, while a
cut-off of 250 μg/g gave 80% and 82%, respectively.11
See online supplementary appendix 1 for a tabulated
form of the studies involving FC cut-offs for screening
for IBD.
Despite the increasing number of studies involving
utility of FC there has been limited study on patients
who have a FC value which falls within the ‘intermediate’
group deﬁned as levels of 50–250 μg/g of feces. While
these patients may still have underlying organic GI disease,
current opinion suggests that the FC assay should be
repeated 4–6 weeks later to determine if inﬂammation is
improving or worsening. Although in reality an intermedi-
ate result may still be referred to secondary care if clinical
suspicion is high for underlying IBD, our local guidance is
in accordance with these ranges (see ﬁgure 1).
The aim of this study was to determine the 12-month
clinical outcomes of patients with an intermediate raised
FC value. There have been, to the best of our knowl-
edge, no published studies which look at clinical out-
comes in this group of patients and proportions
remaining in secondary/tertiary care follow-up.
Figure 1 Local Guidelines for GPs to determine the usefulness of FC in those with chronic diarrhoea.
▸ Do NOT use FC for bowel cancer.
▸ Do NOT use FC for infection.
▸ DO give your patient a labelled stool pot; 2p-sized amount of sample is sufﬁcient (solid stool is best).
▸ DO ask them to bring it to their local hospital/GP to send to BIOCHEMISTRY (not microbiology)—stable at room temp.
▸ DO ﬁll in as much clinical information as possible, including symptoms and duration.
▸ DO send a separate sample to microbiology for M, C and S unless infection has already been excluded.
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MATERIALS AND METHODS
FC samples
FC test results from July 2012 to October 2013 in the
University Hospital Coventry & Warwickshire (UHCW)
pathology database were reviewed. Tests were requested
by primary care and secondary/tertiary care physicians
from the Warwickshire region, a catchment population
of 1 million. Outcomes at 12 months were linked to
index FC result. We have not excluded patients with
other GI conditions, organic or inorganic, as we want to
provide an insight into how FC testing is currently being
used in real-world practice.
Clinical data collection
Clinical information was collected from review of the
central base UHCW (tertiary catchment of 1m popula-
tion) clinical results reporting system and the corre-
sponding systems in neighbouring district hospitals
(Warwick and George Eliot Hospitals). If no information
was found then general practitioners (GPs) were con-
tacted for further details.
Owing to the heterogeneous nature of the data collec-
tion sources, clinical details such as symptoms and medi-
cation which may affect FC values (eg, non-steroidal
anti-inﬂammatory drugs (NSAIDs) or proton pump inhi-
bitors (PPIs)) were often unavailable or poorly recorded,
especially for the general practice patients. These factors
were not considered here due to the lack, or incomplete-
ness, of the data.
FC sample analysis
Standardised laboratory protocol at UHCW for FC ana-
lysis was used. A 100 mg quantity of stool was weighed
and dispensed into an analysis pot using a 10 μL inocula-
tion loop. As per local protocol, ﬁrst morning sample was
requested. The exact weight was recorded and 5 mL of
extraction buffer added. The samples were then vortexed
for 30 min in order to ensure complete dissolution, and
then centrifuged using an Eppendorf centrifuge. The
supernatant was then removed for analysis using the
Immunodiagnostik PhilCal ELISA method.
Ethics
Ethical guidance was obtained from the Coventry and
Warwick NRES Committee. As this study was evaluating a
test already in clinical practice, no further ethical
approval was required.
RESULTS
A total of 495 patients were identiﬁed; 52 paediatric
patients (aged <16 years) were excluded. Of the re-
maining, there were 365 (82%) with a normal FC
result (<50 μg/g), 48 (11%) with an intermediate
result (50–250 μg/g), and 30 (7%) with a high result
(>250 μg/g). Long-term clinical data was available in
41 of the intermediate results. The mean age was
44 years (SD 19.0). There were 17 men (41%) and 24
women (59%). The mean FC for the intermediate
cohort was 130 μg/g (SD 58).
Two persons (4.8%) were known IBD patients under
ongoing secondary care for their condition. They were
included as we wished to provide a ‘snapshot’ of the
usage of FC testing in our centre, including that of
already known IBD patients under surveillance. A total
of 28 (68%) patients with an intermediate FC result
were referred to secondary/tertiary gastroenterology
care by their primary care physicians, with 11 (27%)
managed in primary care. Only one patient had a repeat
FC sample sent, and this remained moderately raised.
The patient subsequently had normal investigations and
was discharged.
A total of 29 (71%) patients with an intermediate FC
result went on to have a colonoscopy, with 8 (20%) also
undergoing a CT scan, and a further 7 (17%) undergo-
ing an MRI. Only eight patients out of the 41 for whom
clinical information was available did not undergo any
investigations. These patients were those who were not
referred to secondary care. This would suggest that an
intermediate result does not reduce the number of
colonoscopies or imaging investigations being done.
The diagnoses of intermediate FC results were:
▸ Eight new cases of IBD diagnosed within the 41
patients (19%; SE6.1%) with FC levels ranging from
81 to 218 μg/g. All underwent colonoscopies:
– Three (7.3%) were diagnosed with Crohn’s disease
(Montreal Classiﬁcation: 1 L2 (colonic); 2 L3
(ileocolonic);
– Three (7.3%) were diagnosed with ulcerative colitis
(UC) (Montreal Classiﬁcation: 2 E1 (proctitis); 1
E2 (left sided);
– Two (4.7%) with IBD unspeciﬁed.
▸ Six (15%) were diagnosed with other organic GI con-
ditions, including bile salt malabsorption, diverticular
disease and carcinoid.
▸ Eleven (27%; SE 7%) were diagnosed with IBS.
▸ Fourteen (34%) remained undiagnosed, however, 8
(19%) of these 14 were not referred to secondary
care by their GP. The reasons for this are unknown;
their symptoms may have settled spontaneously or the
patients themselves may have declined referral:
– Of the six undiagnosed patients (15%) who were
referred to secondary care
– Three (7.3%) were discharged after investigation
with no cause found for the raised FC, with their
symptoms having resolved;
– Three (7.3%) were still under investigation for
other causes of the intermediate FC result, for
example, small bowel bacterial overgrowth.
See table 1 and ﬁgure 2 for a further breakdown of
these results.
The OR for a new diagnosis of IBD with an intermedi-
ate result compared to a normal FC result was 26.6. The
OR of a new diagnosis of IBS with an intermediate result
compared to a normal FC result was 0.54. The OR of
remaining in secondary care 12 months after diagnosis
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with an intermediate FC result was 3.6 compared to a
normal FC result.
Twelve months after their initial FC test, 14 (34%) of
the cohort remained under ongoing secondary/tertiary
care for their conditions, with 14 (34%) discharged back
to their primary care physicians. The remainder were
managed in primary care.
Subgroup analysis of the intermediate patients was
conducted below and above 100 μg/g threshold; 18
(44%) of the intermediate group had FC<100 μg/g,
while 23 (56%) had FC>100 μg/g. For the <100 μg/g
group, 14 (78%) were in primary care 12 months after
index FC test compared with 13 (57%) of >100 μg/g
group at the same time point. Three (17%) with
<100 μg/g received a new diagnosis of IBD compared
with ﬁve (22%) with >100 μg/g group. One patient in
each of the <100 μg/g group and the >100 μg/g, respect-
ively, were known IBD patients, with 2 (11%) and 3
(13%) patients, respectively, being diagnosed with
non-IBD organic GI conditions including bile acid malab-
sorption, diverticular disease and rectal carcinoid; 28% of
<100 μg/g cohort and 26% of >100 μg/g cohort were
diagnosed with IBS; while 38% of <100 μg/g and 35% of
>100 μg/g groups did not receive a formal diagnosis. No
Table 1 Patient demographics and FC values per FC category of low, intermediate and high over 12 months
FC <50 μg/g FC 50–250 μg/g FC >250 μg/g
Mean age (SD) 39 (15)
38 (13) 44 (19) 39 (16)
Male:female (%) 36:64
35:65 42:58 35:65
Mean FC μg/g (SD) 22 (5.0) 130 (58) 784 (573)
Referred to secondary care (n) 66.3% (138) 68.3% (28) 57.7%
Remain in secondary care at 12 months postindex FC (n) 9.1% (19) 34.1% (14) 73.1% (15)
Diagnoses
Pre-existing IBD (n) 3.4% (7) 4.8% (2) 23% (6)
New diagnosis IBD (n) 1.0% (2) 19% (8) 38.4% (10)
Other organic GI diagnosis (n) 13% (27) 14.6% (6) 3.8% (1)
Diagnosis IBS (n) 40.4% (84) 26.8% (11) 7.7% (2)
Undiagnosed or awaiting diagnosis (n) 41.8% (87) 34.1% (14) 26.9% (7)
FC, fecal calprotectin; GI, gastrointestinal; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome.
Figure 2 Flow chart of Intermediate Fecal Calprotectin (FC) diagnoses.
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statistical differences were noted between these two
groups. See table 2 for the subgroup analysis results.
DISCUSSION
Our study provides some insight into the ‘real-world’ use
of FC testing in primary and secondary care. An inter-
mediate or raised FC result increases the probability of
remaining under secondary care 12 months after the
index FC test—34% of intermediate results were still in
secondary care 12 months after index FC, compared
with 9.1% of the normal group and 73% for the raised
group. This reﬂects the increasing likelihood of a diag-
nosis of IBD or another organic GI disease with inter-
mediate or raised FC results.
A new diagnosis of IBD was made in 19% of patients
with an intermediate FC result, compared with 1% for
normal results and 37% for raised results. These ﬁnd-
ings suggest that an initial intermediate FC result gives
an OR of 26.6 for receiving a diagnosis of IBD compared
to a normal FC result, and an OR of 3.6 for remaining
in secondary care 12 months after index FC result for
intermediate results compared to a normal FC result.
This would seem to increase the evidence for suggesting
that intermediate FC results should undergo retesting
4–6 weeks later before referral to secondary care is
made. Of note, a third in this group had no ﬁnal diag-
nosis at 12 months, with most of these arising from
primary care. Unfortunately, no repeat FC specimens
were sent by primary care to determine if the intermedi-
ate result was consistent or transient.
Subgroup analysis of the intermediate group does
not show a clinically signiﬁcant difference between
the <100 μg/g group and the >100 μg/g. There were
similar numbers for: new IBD diagnoses made (17%
(<100 μg/g) vs 22% (>100 μg/g)); other organic GI dis-
eases (11% vs 13%), and IBS diagnoses (28% vs 26%).
Therefore, based on this study group and usefulness
of the ELISA Phical methods, there is no suggestion
that the cut-off value for a normal FC result alters
diagnostic yield if it were raised to 100 μg/g.
NICE guidelines on FC usage do not currently set an
age cut-off for FC testing. NICE IBS guidelines use an
age cut-off >50 as a red ﬂag for change in bowel habit.
Local guidelines state that FC testing should not be
used over the age of 40 years due to the rising inci-
dence of bowel cancer. Rather, such patients with a
change in bowel habit or diarrhoea should undergo
endoscopic investigation. In this study, we found that the
mean age of patients undergoing FC testing was
39 years, with 40% older than 40 years and 19% older
than 50 years. Within the intermediate group, 46% met
local guidelines on FC testing and 66% met NICE guide-
lines’ recommended red ﬂag cut-off of <50 years. The
oldest patient to undergo FC testing was 89 years. This
would suggest that there needs to be greater education
and awareness about the strengths and limitations of FC
testing in aiding with diagnosis or exclusion of organic
GI diseases, principally IBD.
A limitation in this study is the heterogeneous clinical
data, which comprised both primary and secondary care
data, which resulted in incomplete clinical details such
as symptoms and medications, including NSAIDs, across
all FC ranges. However, the objectives of this study were
to understand the way in which FC testing is currently
being used in our region. We have attempted to provide
a ‘real-world’ snapshot of how FC testing is being used
in primary and secondary care settings, with some not
receiving a deﬁnitive diagnosis. NICE appraisal did raise
the issue of spectrum bias because most of the studies in
the assessment report5 came from secondary care set-
tings. Unfortunately, the numbers of patients in our
study, and the lack of data on long-term outcomes on a
substantial number of those with normal results, make it
impossible for us to analyse screening parameters, such
as NPV, separately by source.
Further studies are needed to determine the long-
term clinical outcomes in patients undergoing FC
testing in both primary and secondary care, to aid inter-
pretation of intermediate raised FC results. It could
encourage the use of repeat FC testing for intermediate
results, rather than immediate referral to secondary care
for further investigation. Better education of the indica-
tions, potential confounding drugs, and age issues with
FC testing would provide more efﬁcient use of FC
testing and would allow for far clearer interpretation of
the true meaning of intermediate results.
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Table 2 Outcome subanalysis of FC intermediate groups;
<100 and >100 μg/g
FC<100
(n=18)
FC>100
(n=23)
In primary care 12 months
postindex FC (%)
78% (n=14) 57% (n=13)
New diagnosis of IBD 17% (n=3) 22% (n=5)
Known IBD 5.6% (n=1) 4.3% (n=1)
Other organic GI diagnosis 11% (n=2) 13% (n=3)
IBS diagnosis 28% (n=5) 26% (n=6)
others 38.4% 34.7%
FC, fecal calprotectin; GI, gastrointestinal; IBD, inflammatory
bowel disease; IBS, irritable bowel syndrome.
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